Luo Pengfei, Li Zhimin, He Haodong, Tang Yuanbin, Zeng Lijun, Luo Lunqi, Ouyang Lianjie, Wen Meiling, Li Yuehua, Jiang Yongjun
Department of Oncology, The Central Hospital of Yongzhou, Yongzhou, Hunan, China.
Department of Oncology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
FASEB J. 2025 Mar 31;39(6):e70345. doi: 10.1096/fj.202401088R.
The ribophorin family, including RPN1, has been associated with tumor progression, but its specific role in pan-cancer dynamics remains unclear. Using data from TCGA, GTEx, and Ualcan databases, we investigated the relationship of RPN1 with prognosis, genomic alterations, and epigenetic modifications across various cancers. Differential analysis revealed elevated RPN1 expression in multiple cancer types, indicating a potential prognostic value. Amplification was the predominant mutation type of RPN1 in pan-cancer, with notable correlations with DNA methylation and copy number variation. Gene set variation analysis identified RPN1's involvement in cancer development, immunity, and metabolism. Additionally, RPN1 expression correlated with the tumor microenvironment, immune response factors, and response to anti-tumor therapies. Functional validation in triple-negative breast cancer, glioblastoma, and bladder cancer cell lines demonstrated the role of RPN1 in tumor cell proliferation and migration. Our findings highlight RPN1 as a potential biomarker for cancer diagnosis and treatment response in pan-cancer therapy.
包括RPN1在内的核糖体结合蛋白家族与肿瘤进展相关，但其在泛癌动态中的具体作用仍不清楚。利用来自TCGA、GTEx和Ualcan数据库的数据，我们研究了RPN1与各种癌症的预后、基因组改变和表观遗传修饰之间的关系。差异分析显示多种癌症类型中RPN1表达升高，表明其具有潜在的预后价值。扩增是泛癌中RPN1的主要突变类型，与DNA甲基化和拷贝数变异显著相关。基因集变异分析确定RPN1参与癌症发展、免疫和代谢。此外，RPN1表达与肿瘤微环境、免疫反应因子以及抗肿瘤治疗反应相关。在三阴性乳腺癌、胶质母细胞瘤和膀胱癌细胞系中的功能验证表明RPN1在肿瘤细胞增殖和迁移中的作用。我们的研究结果突出了RPN1作为泛癌治疗中癌症诊断和治疗反应潜在生物标志物的作用。
